Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Ipilimumab + Nivolumab |
| Indication/Tumor Type | esophagus squamous cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org). | 35914638 detail... |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2A) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic esophagus squamous cell carcinoma (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... | |
| ESMO Clinical Practice Guidelines | Full reference... | |
| (35914638) | Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |